AMBIKA AMBLEE, MD
Internal Medicine Physician in CHICAGO, Illinois. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What the federal data shows
AMBIKA AMBLEE, MD reported a CMS MIPS final score of 84.5729/100 — above the 83.1 national average — and filed 274 Medicare Part D claims in 2023.
- 84.5729/100
- MIPS score · +1 vs avg
- 274
- Part D claims, 2023
- 37%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.
AMBIKA AMBLEE, MD's MIPS score vs every scored U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure
85 45th percentile higher than 45% of 477,587 scored providers
Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
AMBIKA AMBLEE, MD practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about AMBIKA AMBLEE, MD?
Near national averagePrimary specialty
Medicare Part D claims
MIPS final score
Specialty distribution in Illinois
How Internal Medicine Physician compares to other specialties among Illinois providers
Internal Medicine Physician share within Illinois
Internal Medicine Physician is one of the more visible NUCC categories in Illinois
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Medicare quality performance — MIPS
AMBIKA AMBLEE, MD's 2023 MIPS final score plotted against the Internal Medicine Physician national average
- MIPS Final Score
- 84.5729/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Internal Medicine Physician) — 84.5729/100 vs national avg 83.1
Quality benchmarks
- National MIPS avg 2023 reporting year
- Quality dim CMS Quality category
- Cost dim CMS Cost category
- Specialty volume Internal Medicine Physician US NPIs
84.5729/100 MIPS final score — 1.5 pts above the 83.1 national average
Quality, Cost, Promoting Interoperability, and Improvement Activities composite score for the 2023 performance year. Specialty: Internal Medicine Physician. Quality dim: 60.2504. Cost dim: 67.0015.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
AMBIKA AMBLEE, MD appears in the CMS NPPES registry as a Internal Medicine Physician provider holding MD credentials at 1901 W HARRISON ST, CHICAGO, IL, 60612, with a listed phone of (312) 864-6519. NPI 1225090590 was issued on 04/03/2006. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what AMBLEE most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 274 prescription claims written by this provider, covering 88 Medicare beneficiaries and totaling roughly $193K in drug spend, split 63% brand-name and 37% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 84.5729/100 for the 2023 performance year (Quality 60.2504, Cost 67.0015), compared with the national average of 83.1.
Internal Medicine Physician is a high-volume specialty nationwide, with 172,858 enrolled providers across 56 states and an average of 2,716 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1225090590 |
|---|---|
| Specialty | Internal Medicine Physician |
| Credentials | MD |
| Gender | Female |
| NPI Issued | 04/03/2006 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm AMBIKA AMBLEE, MD's current license status, disciplinary history, and board certifications with the Illinois Department of Financial and Professional Regulation in Illinois before relying on this page for a clinical or care decision.
How we sourced this profile
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
Reporting: Group practice
License & disciplinary context — Illinois IDFPR 2023 annual report
Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~42K Illinois medical licensees in 2023 — they are NOT specific to AMBIKA AMBLEE, MD. To verify AMBIKA AMBLEE, MD's current license status, search the IDFPR public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
IDFPR publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Illinois disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Brand-heavy
63% brand-name claims vs 37% generic, on 274 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 541
- Total Day Supply
- 15,815
- Brand vs Generic
- 63% brand / 37% generic
- Brand Drug Cost
- $190K
- Generic Drug Cost
- $2K
Patient Demographics
- Average Patient Age
- 69.8 years
- Avg HCC Risk Score
- 1.74
- Gender Split
- 65% female / 35% male
- Age Distribution
- <65: 16, 65-74: 54, 75-84: N/A, 85+: N/A
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What AMBIKA AMBLEE, MD prescribes most
Top Medicare Part D drugs by claim count, 2023
- Levothyroxine Sodium
Levothyroxine Sodium
25 claims
- Metformin Hcl
Metformin Hcl
17 claims
- Novolin 70-30
Novolin 70-30
14 claims
- Novolog Flexpen
Novolog Flexpen
14 claims
- Jardiance
Jardiance
13 claims
- Victoza 3-Pak
Victoza 3-Pak
13 claims
| Drug | Claims |
|---|---|
| Levothyroxine Sodium | 25 |
| Metformin Hcl | 17 |
| Novolin 70-30 Insulin Nph Hum/Reg Insulin Hm | 14 |
| Novolog Flexpen Insulin Aspart | 14 |
| Jardiance Empagliflozin | 13 |
| Victoza 3-Pak Liraglutide | 13 |
| Basaglar Kwikpen U-100 "Insulin Glargine | N/A |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Internal Medicine Physician Overview
How AMBIKA AMBLEE, MD fits within the Internal Medicine Physician landscape nationally.
AMBIKA AMBLEE, MD's 274 claims are below the specialty average of 2,716.
Nearby Internal Medicine Physician Providers in Illinois
Other clinicians with the same primary specialty enrolled in Illinois, drawn from the same CMS NPPES roster as AMBLEE.
Compare Internal Medicine Physician nationally: see state-by-state distribution →
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore Illinois
Frequently Asked Questions
What is AMBIKA AMBLEE, MD's specialty? ▼
How much does AMBIKA AMBLEE, MD prescribe under Medicare Part D? ▼
What is AMBIKA AMBLEE, MD's Medicare quality score? ▼
Where is AMBIKA AMBLEE, MD located? ▼
What is AMBIKA AMBLEE, MD's NPI number? ▼
Does AMBIKA AMBLEE, MD prescribe more brand-name or generic drugs? ▼
How many Internal Medicine Physician providers are there in the US? ▼
What drugs does AMBIKA AMBLEE, MD prescribe most often? ▼
Does AMBIKA AMBLEE, MD accept Medicare? ▼
How can I verify AMBIKA AMBLEE, MD's credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology